Marieke T. Van Der Zwan-Van Der Wal

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant Rejection.

Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant Rejection.

Journal: Clinical transplantation

Published: August 30, 2024

A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection.

A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection.

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Published: July 27, 2023

Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection.

Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection.

Journal: Clinical pharmacology and therapeutics

Published: January 10, 2022

Chronic-active Antibody-mediated Rejection: To Belatacept or Not, That Is the HOT Question.

Chronic-active Antibody-mediated Rejection: To Belatacept or Not, That Is the HOT Question.

Journal: Transplantation

Published: August 01, 2020

Acquired haemophilia A after alemtuzumab therapy.

Acquired haemophilia A after alemtuzumab therapy.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 31, 2020

Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?

Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?

Journal: Transplantation

Published: March 10, 2020

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection.

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection.

Journal: Frontiers in immunology

Published: February 09, 2020

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients.

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: November 25, 2019

Costimulation Blockade in Kidney Transplant Recipients.

Costimulation Blockade in Kidney Transplant Recipients.

Journal: Drugs

Published: November 22, 2019

Targeted Proteomic Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients.

Targeted Proteomic Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients.

Journal: Therapeutic drug monitoring

Published: March 19, 2019

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients.

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients.

Journal: Transplantation direct

Published: November 01, 2018

The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy.

The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy.

Journal: Annals of transplantation

Published: August 18, 2018

Showing 1-12 of 15

Last Updated: 09/26/2026